Clinical trial

Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC

NCT03526887

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-07-15

PhasePHASE2

Study timeline

Study start (actual)2018-07-15Date precision: day

Registry last updated2025-03-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancerunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Spanish Lung Cancer Grouplead sponsor

Mapped research locations

MadridSpain3 BarcelonaSpain2 ValenciaSpain2 ZaragozaSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03526887 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.